nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.06.2008

Targeting PTPs with small molecule inhibitors in cancer treatment

verfasst von: Zhong-Xing Jiang, Zhong-Yin Zhang

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Protein tyrosine phosphorylation plays a major role in cellular signaling. The level of tyrosine phosphorylation is controlled by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). Disturbance of the normal balance between PTK and PTP activity results in aberrant tyrosine phosphorylation, which has been linked to the etiology of several human diseases, including cancer. A number of PTPs have been implicated in oncogenesis and tumor progression and therefore are potential drug targets for cancer chemotherapy. These include PTP1B, which may augment signaling downstream of HER2/Neu; SHP2, which is the first oncogene in the PTP superfamily and is essential for growth factor-mediated signaling; the Cdc25 phosphatases, which are positive regulators of cell cycle progression; and the phosphatase of regenerating liver (PRL) phosphatases, which promote tumor metastases. As PTPs have emerged as drug targets for cancer, a number of strategies are currently been explored for the identification of various classes of PTP inhibitors. These efforts have resulted many potent, and in some cases selective, inhibitors for PTP1B, SHP2, Cdc25 and PRL phosphatases. Structural information derived from these compounds serves as a solid foundation upon which novel anti-cancer agents targeted to these PTPs can be developed.

Hunter, T. (2000). Signaling—2000 and beyond. Cell, 100, 113–127.PubMedCrossRef

Tonks, N. K. (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nature Reviews. Molecular Cell Biology, 7, 833–846.PubMedCrossRef

Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., et al. (2004). Protein tyrosine phosphatases in the human genome. Cell, 117, 699–711.PubMedCrossRef

Hunter, T. (1998). The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 353, 583–605.PubMedCrossRef

Zhang, Z.-Y. (2001). Protein tyrosine phosphatases: prospects for therapeutics. Current Opinion in Chemical Biology, 5, 416–423.PubMedCrossRef

Arena, S., Benvenuti, S., & Bardelli, A. (2005). Genetic analysis of the kinome and phosphatome in cancer. Cellular and Molecular Life Sciences, 62, 2092–2099.PubMedCrossRef

Ventura, J. J., & Nebreda, A. R. (2006). Protein kinases and phosphatases as therapeutic targets in cancer. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 8, 153–160.

Krause, D. S., & Van Etten, R. A. (2005). Tyrosine kinases as targets for cancer therapy. New England Journal of Medicine, 353, 172–187.PubMedCrossRef

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275, 1943–1947.PubMedCrossRef

10.

Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23 that is mutated in multiple advanced cancers. Nature Genetics, 15, 356–362.PubMedCrossRef

11.

Wang, Z., Shen, D., Parsons, D. W., Bardelli, A., Sager, J., Szabo, S., et al. (2004). Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science, 304, 1164–1166.PubMedCrossRef

12.

Zheng, X. M., Wang, Y., & Pallen, C. J. (1992). Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature, 359, 336–339.PubMedCrossRef

13.

Ponniah, S., Wang, D. Z., Lim, K. L., & Pallen, C. J. (1999). Targeted disruption of the tyrosine phosphatase PTPalpha leads to constitutive downregulation of the kinases Src and Fyn. Current Biology, 9, 535–538.PubMedCrossRef

14.

Su, J., Muranjan, M., & Sap, J. (1999). Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Current Biology, 9, 505–511.PubMedCrossRef

15.

Noguchi, T., Matozaki, T., Horita, K., Fujioka, Y., & Kasuga, M. (1994). Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. Molecular and Cell Biology, 14, 6674–6682.

16.

Tang, T. L., Freeman Jr., R. M., O’Reilly, A. M., Neel, B. G., & Sokol, S. Y. (1995). The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell, 80, 473–483.PubMedCrossRef

17.

Bennett, A. M., Hausdorff, S. F., O’Reilly, A. M., Freeman, R. M., & Neel, B. G. (1996). Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Molecular and Cell Biology, 16, 1189–1202.

18.

Shi, Z. Q., Yu, D. H., Park, M., Marshall, M., & Feng, G. S. (2000). Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Molecular and Cell Biology, 20, 1526–1536.CrossRef

19.

Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., et al. (2001). Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP2, cause Noonan syndrome. Nature Genetics, 29, 465–468.PubMedCrossRef

20.

Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., et al. (2003). Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics, 34, 148–150.PubMedCrossRef

21.

Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., et al. (2004). Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Research, 64, 8816–8820.PubMedCrossRef

22.

Stephens, B. J., Han, H., Gokhale, V., & Von Hoff, D. D. (2005). PRL phosphatases as potential molecular targets in cancer. Advanced Thailand Geographic, 4, 1653–1661.

23.

Blume-Jensen, P., & Hunter, T. (2001). Oncogenic kinase signaling. Nature, 411, 355–365.PubMedCrossRef

24.

Druker, B. J. (2004). Imatinib as a paradigm of targeted therapies. Advanced Cancer Research, 91, 1–30.CrossRef

25.

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350, 2129–2139.PubMedCrossRef

26.

Ostman, A., Hellberg, C., & Bohmer, F. D. (2006). Protein-tyrosine phosphatases and cancer. Nature Reviews. Nature Reviews. Cancer, 6, 307–320.PubMedCrossRef

27.

Elchelby, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Lee Loy, A., et al. (1999). Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science, 283, 1544–1548.CrossRef

28.

Klaman, L. D., Boss, O., Peroni, O. D., Kim, J. K., Martino, J. L., Zabolotny, J. M., et al. (2000). Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Molecular and Cellular Biology, 20, 5479–5489.PubMedCrossRef

29.

Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., et al. (2002). PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proceedings of the National Academy of Sciences of the United States of America, 99, 11357–11362.PubMedCrossRef

30.

Flint, A. J., Tiganis, T., Barford, D., & Tonks, N. K. (1997). Development of “substrate-trapping” mutants to identify physiological substrates of protein tyrosine phosphatases. Proceedings of the National Academy of Sciences of the United States of America, 94, 1680–1685.PubMedCrossRef

31.

Liu, F., & Chernoff, J. (1997). Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor. Biochemical Journal, 327, 139–145.PubMed

32.

Bjorge, J. D., Pang, A., & Fujita, D. J. (2000). Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. Journal of Biological Chemistry, 275, 41439–41446.PubMedCrossRef

33.

Cheng, A., Bal, G. S., Kennedy, B. P., & Tremblay, M. L. (2001). Attenuation of adhesion-dependent signaling and cell spreading in transformed fibroblasts lacking protein tyrosine phosphatase-1B. Journal of Biological Chemistry, 276, 25848–25855.PubMedCrossRef

34.

Liang, F., Lee, S.-Y., Liang, J., Lawrence, D. S., & Zhang, Z. Y. (2005). The role of PTP1B in integrin signaling. Journal of Biological Chemistry, 280, 24857–24863.PubMedCrossRef

35.

Dube, N., Cheng, A., & Tremblay, M. L. (2004). The role of protein tyrosine phosphatase 1B in Ras signaling. Proceedings of the National Academy of Sciences of the United States of America, 101, 1834–1839.PubMedCrossRef

36.

Yarden, Y. (2001). Biology of HER2 and its importance in breast cancer. Oncology, 61(Suppl 2), 1–13.PubMedCrossRef

37.

Hynes, N. E., & Lane, H. A. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews. Cancer, 5, 341–354.PubMedCrossRef

38.

Zhai, Y. F., Beittenmiller, H., Wang, B., Gould, M. N., Oakley, C., Esselman, W. J., et al. (1993). Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Research, 53, 2272–2278.PubMed

39.

Wiener, J. R., Kerns, B. J., Harvey, E. L., Conaway, M. R., Iglehart, J. D., Berchuck, A., et al. (1994). Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. Journal of the National Cancer Institute, 86, 372–378.PubMedCrossRef

40.

Julien, S. G., Dubé, N., Read, M., Penney, J., Paquet, M., Han, Y., et al. (2007). Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nature Genetics, 39, 338–346.PubMedCrossRef

41.

Bentires-Alj, M., & Neel, B. G. (2007). Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Research, 67, 2420–2424.PubMedCrossRef

42.

Zhu, S., Bjorge, J. D., & Fujita, D. J. (2007). PTP1B contributes to oncogenic properties of colon cancer cells through Src activation. Cancer Research, 67, 10129–10137.PubMedCrossRef

43.

Zhang, S., & Zhang, Z.-Y. (2007). PTP1B as a drug target: recent development in PTP1B inhibitor discovery. Drug Discovery Today, 12, 373–381.PubMedCrossRef

44.

Shen, K., Keng, Y. F., Wu, L., Guo, X. L., Lawrence, D. S., & Zhang, Z.-Y. (2001). Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. Journal of Biological Chemistry, 276, 47311–47319.PubMedCrossRef

45.

Sun, J.-P., Fedorov, A. A., Lee, S.-Y., Guo, X.-L., Shen, K., Lawrence, D. S., et al. (2003). Crystal structure of PTP1B in complex with a potent and selective bidentate inhibitor. Journal of Biological Chemistry, 278, 12406–12414.PubMedCrossRef

46.

Xie, L., Lee, S.-Y., Andersen, J. N., Waters, S., Shen, K., Guo, X.-L., et al. (2003). Cellular effects of small molecule PTP1B inhibitors on insulin signalling. Biochemistry, 42, 12792–12804.PubMedCrossRef

47.

Lee, S.-Y., Liang, F., Guo, X.-L., Xie, L., Cahill, S. M., Blumenstein, M., et al. (2005). Design, construction, and intracellular activation of an intramolecularly self-silenced signal transduction inhibitor. Angewandte Chemie. International Edition, 44, 4242–4244.CrossRef

48.

Boutselis, I. G., Yu, X., Zhang, Z. Y., & Borch, R. (2007). Synthesis and cell-based activity of a potent and selective PTP1B inhibitor prodrug. Journal of Medicinal Chemistry, 50, 856–864.PubMedCrossRef

49.

Morrison, C. D., White, C. L., Wang, Z., Lee, S.-Y., Lawrence, D. S., Cefalu, W. T., et al. (2007). Increased hypothalamic PTP1B contribute to leptin resistance with age. Endocrinology, 148, 433–440.PubMedCrossRef

50.

Black, E., Breed, J., Breeze, A. L., Embrey, K., Garcia, R., Gero, T. W., et al. (2005). Structure-based design of protein tyrosine phosphatase-1B inhibitors. Bioorganic & Medicinal Chemistry Letters, 15, 2503–2507.CrossRef

51.

Combs, A. P., Yue, E. W., Bower, M., Ala, P. J., Wayland, B., Douty, B., et al. (2005). Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics. Journal of Medicinal Chemistry, 48, 6544–6548.PubMedCrossRef

52.

Yue, E. W., Wayland, B., Douty, B., Crawley, M. L., McLaughlin, E., Takvorian, A., et al. (2006). Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: synthesis and structure-activity relationships of a peptide scaffold. Bioorganic & Medicinal Chemistry, 14, 5833–5849.CrossRef

53.

Combs, A. P., Zhu, W., Crawley, M. L., Glass, B., Polam, P., Sparks, R. B., et al. (2006). Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic. Journal of Medicinal Chemistry, 49, 3774–3789.PubMedCrossRef

54.

Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., & Shoelson, S. E. (1998). Cell, 92, 441–450.PubMedCrossRef

55.

Mohi, M. G., & Neel, B. G. (2007). The role of Shp2 (PTPN11) in cancer. Current Opinion in Genetics & Development, 17, 23–30.CrossRef

56.

Hatakeyama, M. (2004). Oncogenic mechanisms of the Helicobacter pyroli CagA protein. Nature Reviews. Cancer, 4, 688–694.PubMedCrossRef

57.

Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318, 287–290.PubMedCrossRef

58.

Chen, L., Sung, S. S., Yip, M. L., Lawrence, H. R., Ren, Y., Guida, W. C., et al. (2006). Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Molecular Pharmacology, 70, 562–570.PubMedCrossRef

59.

Coleman, T. R., & Dunphy, W. G. (1994). Cdc2 regulatory factors. Current Opinion in Cell Biology, 6, 877–882.PubMedCrossRef

60.

Hoffmann, I., & Karsenti, E. (1994). The role of cdc25 in checkpoints and feedback controls in the eukaryotic cell cycle. Journal of Cell Science. Supplement, 18, 75–79.PubMed

61.

Nilsson, I., & Hoffmann, I. (2000). Cell cycle regulation by the Cdc25 phosphatase family. Progress in Cell Cycle Research, 4, 107–114.PubMed

62.

Ma, Z. Q., Chua, S. S., DeMayo, F. J., & Tsai, S. Y. (1999). Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B. Oncogene, 18, 4564−4576.PubMed

63.

Yao, Y., Slosberg, E. D., Wang, L., Hibshoosh, H., Zhang, Y.-J., Xing, W.-Q., et al. (1999). Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice. Oncogene, 18, 5159−5166.PubMed

64.

Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J., Loda, M., et al. (1995). Cdc25 phosphatases as potential human oncogenes. Science, 269, 1575–1577.PubMedCrossRef

65.

Cangi, M. G., Cukor, B., Soung, P., Signoretti, S., Moreira Jr., G., Ranashinge, M., et al. (2000). Role of the Cdc25A phosphatase in human breast cancer. Journal of Clinical Investigation, 106, 753–761.PubMedCrossRef

66.

Lyon, M. A., Ducruet, A. P., Wipf, P., & Lazo, J. S. (2002). Dual-specificity phosphatases as targets for antineoplastic agents. Nature reviews. Nature reviews. Drug discovery, 1, 961–976.PubMedCrossRef

67.

Ducruet, A. P., Vogt, A., Wipf, P., & Lazo, J. S. (2005). Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer’s disease. Annual Review of Pharmacology and Toxicology, 45, 725–750.PubMedCrossRef

68.

Gunasekera, S. P., McCarty, P. J., Kelly-Borges, M., Lobkovsky, E., & Clardy, J. (1996). Dysidiolide: a novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. Journal of the American Chemical Society, 118, 8759–8760.CrossRef

69.

Dodo, K., Takahashi, M., Yamada, Y., Sugimoto, Y., Hashimoto, Y., & Shirai, R. (2000). Synthesis of a novel class of cdc25A inhibitors from vitamin D3. Bioorganic & Medicinal Chemistry Letters, 10, 615–617.CrossRef

70.

Horiguchi, T., Nishi, K., Hakoda, S., Tanida, S., Nagata, A., & Okayama, H. (1994). Dnacin A1 and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity. Biochemical Pharmacology, 48, 2139–2141.PubMedCrossRef

71.

Loukaci, A., Le Saout, I., Samadi, M., Leclerc, S., Damiens, E., Meijer, L., et al. (2001). Coscinosulfate, a CDC25 phosphatase inhibitor from the sponge Coscinoderma mathewsi. Bioorganic & Medicinal Chemistry, 9, 3049–3054.CrossRef

72.

Ham, S. W., Park, H. J., & Lim, D. H. (1997). Studies on menadione as an inhibitor of the cdc25 phosphatase. Bioorganic Chemistry, 25, 33–36.CrossRef

73.

Lazo, J. S., Nemoto, K., Pestell, K. E., Cooley, K., Southwick, E. C., Mitchell, D. A., et al. (2002). Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Molecular Pharmacology, 61, 720–728.PubMedCrossRef

74.

Contour-Galcera, M. O., Sidhu, A., Prevost, G., Bigg, D., & Ducommun, B. (2007). What’s new on Cdc25 phosphatase inhibitors. Pharmacology & Therapeutics, 115, 1–12.CrossRef

75.

Sohn, J., Kiburz, B., Li, Z., Deng, L., Safi, A., Pirrung, M. C. et al. (2003). Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones. Journal of Medicinal Chemistry, 46, 2580–2588.PubMedCrossRef

76.

Diamond, R. H., Cressman, D. E., Laz, T. M., Abrams, C. S., & Taub, R. (1994). PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Molecular and Cellular Biology, 14, 3752–3762.PubMed

77.

Wang, J., Kirby, C. E., & Herbst, R. (2002). The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. Journal of Biological Chemistry, 277, 46659–46668.PubMedCrossRef

78.

Cates, C. A., Michael, R. L., Stayrook, K. R., Harvey, K. A., Burke, Y. D., Randall, S. K., et al. (1996). Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatase. Cancer Letters, 110, 49–55.PubMedCrossRef

79.

Matter, W. F., Estridge, T., Zhang, C., Belagaje, R., Stancato, L., Dixon, J., et al. (2001). Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochemical and Biophysical Research Communications, 283, 1061–1068.PubMedCrossRef

80.

Zeng, Q., Dong, J. M., Guo, K., Li, J., Tan, H. X., Koh, V., et al. (2003). PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Research, 63, 2716–2722.PubMed

81.

Werner, S. R., Lee, P. A., DeCamp, M. W., Crowell, D. N., Randall, S. K., & Crowell, P. L. (2003). Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases. Cancer Letters, 202, 201–211.PubMedCrossRef

82.

Saha, S., Bardelli, A., Buckhaults, P., Velculescu, V. E., Rago, C., St Croix, B., et al. (2001). A phosphatase associated with metastasis of colorectal cancer. Science, 294, 1343–1346.PubMedCrossRef

83.

Bardelli, A., Saha, S., Sager, J. A., Romans, K. E., Xin, B., Markowitz, S. D., et al. (2003). PRL-3 expression in metastatic cancers. Clinical Cancer Research, 9, 5607–5615.PubMed

84.

Kato, H., Semba, S., Miskad, U. A., Seo, Y., Kasuga, M., & Yokozaki, H. (2004). High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clinical Cancer Research, 10, 7318–7328.PubMedCrossRef

85.

Liang, F., Liang, J., Wang, W. Q., Sun, J. P., Udho, E., & Zhang, Z. Y. (2007). PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. Journal of Biological Chemistry, 282, 5413–5419.PubMedCrossRef

86.

Fiordalisi, J. J., Keller, P. J., & Cox, A. D. (2006). PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Research, 66, 3153–3161.PubMedCrossRef

87.

Achiwa, H., & Lazo, J. S. (2007). PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Research, 67, 643–650.PubMedCrossRef

88.

Rouleau, C., Roy, A., St Martin, T., Dufault, M. R., Boutin, P., Liu, D., et al. (2006). Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function. Clinical Cancer Research, 5, 219–229.

89.

Pathak, M. K., Dhawan, D., Lindner, D. J., Borden, E. C., Farver, C., & Yi, T. (2002). Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Molecular Cancer Therapeutics, 1, 1255–1264.PubMed

90.

Ahn, J. H., Kim, S. J., Park, W. S., Cho, S. Y., Ha, J. D., Kim, S. S., et al. (2006). Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorganic & Medicinal Chemistry Letters, 16, 2996–2999.CrossRef

91.

Choi, S. K., Oh, H. M., Lee, S. K., Jeong, D. G., Ryu, S. E., Son, K. H., et al. (2006). Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3). Natural Product Research, 20, 341–346.PubMedCrossRef

92.

Jeong, D. G., Kim, S. J., Kim, J. H., Son, J. H., Park, M. R., Lim, S. M., et al. (2005). Trimeric structure of PRL1 phosphatase reveals an active enzyme conformation and regulation mechanisms. Journal of Molecular Biology, 345, 401–413.PubMedCrossRef

93.

Sun, J. P., Wang, W. Q., Yang, H., Liu, S., Liang, F., Fedorov, A. A., et al. (2005). Structure and biochemical properties of PRL1, a phosphatase implicated in cell growth, differentiation, and tumor invasion. Biochemistry, 44, 12009–12021.PubMedCrossRef

94.

Sun, J.-P., Luo, Y., Yu, X., Wang, W.-Q., Zhou, B., Liang, F., et al. (2007). Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for the PRL1-mediated cell growth and migration. Journal of Biological Chemistry, 282, 29043–29051.PubMedCrossRef

Titel: Targeting PTPs with small molecule inhibitors in cancer treatment
verfasst von: Zhong-Xing Jiang
Zhong-Yin Zhang
Publikationsdatum: 01.06.2008
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9113-3

Springer Medizin

Targeting PTPs with small molecule inhibitors in cancer treatment

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer

SV40 small T antigen and PP2A phosphatase in cell transformation

Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development

MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer

Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species

The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie